UPMC Scleroderma Center (Systemic Sclerosis and Localized Sclerosis)
The UPMC Scleroderma Center has specialized in the diagnosis and treatment of scleroderma for more than 50 years and has evaluated and treated more than 5,000 patients. Our success at managing and treating scleroderma stems from the comprehensive care that is tailored to the needs of each patient.
Our physicians are recognized as leaders in the field, having published more than 300 articles on scleroderma in medical literature.
About scleroderma
Scleroderma literally means hardening and thickening (sclero) of the skin (derma).
There are two forms of the disease.
- Systemic scleroderma (systemic sclerosis) is capable of causing serious, potentially fatal internal organ involvement.
- Localized scleroderma affects the skin only.
Both systemic and localized scleroderma are disorders that activate the immune system, leading to tissue damage and eventually resulting in excessive deposits of collagen (fibrosis).
Doctors have identified distinct subsets of scleroderma patients, which helps them direct treatment approaches and assess future risks.
View diagnosis of this condition.